TABLE 1.
Patient demographics
| Demographics | ITT, n = 49 | Evaluable, n = 37 |
|---|---|---|
| Age, years ± SD | 66.9 ± 10.4 | 66.9 ± 10.6 |
| Gender, female, n (%) | 24 (49.0%) | 17 (45.9%) |
| ECOG performance status at screening | ||
| Score of 0, n (%) | 15 (30.6%) | 12 (32.4%) |
| Score of 1, n (%) | 33 (67.4%) | 25 (67.6%) |
| Score of 2, n (%) | 1 (2.0%) | 0 (0.0%) |
| Body mass index ± SD | 23.6 ± 4.4 | 23.5 ± 4.3 |
| Race, n (%) | ||
| White | 44 (89.8%) | 34 (91.9%) |
| Black or African American | 3 (6.1%) | 2 (5.4%) |
| Asian | 2 (4.1%) | 1 (2.7%) |
| Prior radiotherapy, n (%) | 15 (30.6%) | 12 (32.4%) |
| Prior surgery, n (%) | 19 (38.8%) | 16 (43.2%) |
| Prior lines of therapy, n (%) | ||
| 1 | 7 (14.3%) | 5 (13.5%) |
| 2 | 24 (49.0%) | 18 (48.6%) |
| 3 | 10 (20.4%) | 9 (24.3%) |
| 4+ | 8 (16.3%) | 5 (13.5%) |
| Prior systemic therapy, n (%) a | ||
| Gemcitabine | 42 (85.7%) | 32 (86.5%) |
| 5‐fluorouracil | 40 (81.6%) | 31 (83.8%) |
| Irinotecan | 37 (75.5%) | 28 (75.7%) |
| Platinum | 36 (73.5%) | 28 (75.7%) |
| FOLFIRINOX or mFOLFIRINOX | 32 (65.3%) | 23 (62.2%) |
| FOLFOX or OFF | 1 (2.2%) | 1 (2.7%) |
| FOLFIRI or IFL | 9 (18.4%) | 7 (18.9%) |
| Taxanes | 35 (71.4%) | 27 (73.0%) |
| Nab‐paclitaxel | 34 (69.4%) | 26 (70.3%) |
| Docetaxel | 1 (2.0%) | 1 (2.7%) |
| PARP inhibitors | 2 (4.1%) | 1 (2.7%) |
| Immunotherapy | 6 (12.2%) | 3 (8.1%) |
| Other investigational agents | 9 (18.4%) | 7 (18.9%) |
Abbreviation: ITT, intent‐to‐treat.
a
Indicates exposure to drug alone, or as part of any regimen.